Loading...
The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
Introduction. Simultaneous inhibition of programmed cell death-1 (PD-1)/PD-L1 immune checkpoint and VEGF/VEGFR signaling has a synergistic antitumor effect in preclinical models. This article presents the results of the phase III study JAVELIn Renal 101 (NCT02684006), as well as the experience...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Russo |
| Udgivet: |
Remedium Group LLC
2021-06-01
|
| Serier: | Медицинский совет |
| Fag: | |
| Online adgang: | https://www.med-sovet.pro/jour/article/view/6209 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|